OncoCyte Corporation to Participate in the Benchmark Company, LLC Micro Cap Discovery One-on-One Conference
November 27 2017 - 7:00AM
OncoCyte Corporation (NYSE American:OCX), a
developer of novel, non-invasive blood based tests for the early
detection of cancer, announced today that William Annett, President
and Chief Executive Officer, and Mitch Levine, Chief Financial
Officer, will participate in the Benchmark Company, LLC Micro Cap
Discovery One-on-One Conference. The conference will take place on
Thursday, December 14, 2017, at the Palmer House Hilton in Chicago,
Illinois. Mr. Annett and Mr. Levine will provide investors with a
corporate overview, including discussion about DetermaVu™, the
Company’s liquid biopsy lung cancer diagnostic test.
About OncoCyte Corporation
OncoCyte is focused on the development and
commercialization of novel, non-invasive blood and urine (“liquid
biopsy”) diagnostic tests for the early detection of cancer to
improve health outcomes through earlier diagnoses, to reduce the
cost of care through the avoidance of more costly diagnostic
procedures, including invasive biopsy and cystoscopic procedures,
and to improve the quality of life for cancer patients. While
current biopsy tests use invasive surgical procedures to provide
tissue samples in order to determine if a tumor is benign or
malignant, OncoCyte is developing a next generation of diagnostic
tests that will be based on liquid biopsies using blood or urine
samples. OncoCyte’s pipeline products are intended to be
confirmatory diagnostics for detecting lung, breast and bladder
cancer. OncoCyte’s diagnostic tests are being developed using
proprietary sets of genetic and protein markers that differentially
express in specific types of cancer.
DetermaVu™ is a trademark of OncoCyte
Corporation.
Forward Looking Statements
Any statements that are not historical fact
(including, but not limited to statements that contain words such
as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates” and similar expressions) are forward-looking
statements. These statements include those pertaining to the
implementation and results of research, development, clinical
trials and studies, commercialization plans, future financial
and/or operating results, and future opportunities for OncoCyte,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential diagnostic tests or products,
uncertainty in the results of clinical trials or regulatory
approvals, the capacity of our third-party supplied blood sample
analytic system to provide consistent and precise analytic results
on a commercial scale, the need and ability to obtain future
capital, and maintenance of intellectual property rights, and the
need to obtain third party reimbursement for patients’ use of any
diagnostic tests we commercialize. Actual results may differ
materially from the results anticipated in these forward-looking
statements and accordingly as such statements should be evaluated
together with the many uncertainties that affect the business of
OncoCyte, particularly those mentioned in the “Risk Factors” and
other cautionary statements found in OncoCyte’s Securities and
Exchange Commission filings. OncoCyte disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.
Investor Contact:
EVC Group, Inc.Matt Haines / Michael Polyviou917-733-9297 /
212-850-5600mhaines@evcgroup.com / mpolyviou@evcgroup.com
Financial Media Contact:
GIBSON Communications, LLCTom
Gibson201-476-0322tom@tomgibsoncommunications.com
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Apr 2023 to Apr 2024